The annual Digestive Disease Week was held this week in San Diego and attracted approximately 16,000 participants from around the world, including researchers and academicians in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. 

The event was sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, and Society for Surgery of the Alimentary Tract.

In one study presented at the meeting, Lisa Backus, MD, of the Veterans Affairs Palo Alto Health Care System in California, and colleagues evaluated the efficacy of ledipasvir/sofosbuvir plus or minus ribavirin (LS±RBV) and ombitasvir/paritaprevir/ritonavir plus dasabuvir plus or minus ribavirin (OPrD±RBV) in 6,961 patients with genotype 1 hepatitis C virus (HCV).

Continue Reading

“We found that patients in this real-world cohort had sustained viral response (SVR) rates similar to those seen in clinical trials,” Backus said. “In multivariate models, African-American race, body mass index (BMI) ≥30 kg/m², fibrosis-4 (FIB-4) score >3.25, and treatment with OPrD plus RBV compared to LS were independent negative predictors of SVR.”

In those patients who completed a full 12-week course of treatment, the researchers also concluded that African-American race and treatment with OPrD plus RBV no longer had a significant impact on odds of SVR, likely arising from excess early treatment discontinuation. However, FIB-4 and BMI ≥30 kg/m² remained significant negative predictors of SVR.

“We now have extremely effective treatment options but patients need to be screened and diagnosed with HCV in order to get treated,” Backus said. “In addition, adherence is essential to improved outcomes. Clinicians need to work with patients to make sure they complete a full 12 weeks of treatment.”

Learn more about HCV treatment options in this video from Norah Terrault, MD, from the University of California, San Francisco, who was interviewed at DDW 2016 this week.


1. Backus LI, Belperio PS, Shahoumian TA, Loomis T, Mole L. Comparative Effectiveness of Ledipasvir/Sofosbuvir±Ribavirin and Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin in 6,961 Genotype 1 Patients Treated in Routine Medical Practice. Abstract No. 501. Presented at: DDW 2016. May 21-24, 2016. San Diego.